Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Exelixis's interest expense for the
three
months ended in Dec. 2023 was $ 0 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Exelixis's Operating Income for the
three
months ended in Dec. 2023 was $ 82 Mil. Exelixis's Interest Expense for the
three
months ended in Dec. 2023 was $ 0 Mil.
GuruFocus does not calculate Exelixis's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Exelixis Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (NAS:EXEL) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Exelixis's Interest Expense for the
three
months ended in Dec. 2023 was $0 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $82 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $190 Mil.
Exelixis's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| GuruFocus does not calculate Exelixis's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Exelixis Inc has enough cash to cover all of its debt. Its financial situation is stable.
Exelixis (Exelixis) Business Description
Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
| Patrick J. Haley |
officer: Sr. Vice President, Commercial |
210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
| Jeffrey Hessekiel |
officer: EVP and General Counsel |
210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
| David Edward Johnson |
director |
590 MADISON AVENUE, NEW YORK NY 10022 |
| Dana Aftab |
officer: CSO/EVP Disc & Trans Research |
EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
| Amy C. Peterson |
officer: EVP Prod Dev & Med Aff & CMO |
C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
| Christopher J. Senner |
officer: EVP and CFO |
210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
| Tomas J. Heyman |
director |
C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Bob Oliver |
director |
C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
| Caligan Partners Lp |
director, other: See Remarks |
515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022 |
| Jack L Wyszomierski |
director |
SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000 |
| Alan M Garber |
director |
3355 MILTON COURT, MOUNTAIN VIEW CA 94040 |
| Carl B Feldbaum |
director |
C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511 |
| Peter Lamb |
officer: EVP, Discovery Research & CSO |
PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511 |
| George Poste |
director |
515 GALVESTON DR, REDWOOD CITY CA 94063 |
| Lance Willsey |
director |
C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083 |
Exelixis (Exelixis) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EXEL has been successfully added to your 